RU2003127718A - Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости - Google Patents
Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости Download PDFInfo
- Publication number
- RU2003127718A RU2003127718A RU2003127718/15A RU2003127718A RU2003127718A RU 2003127718 A RU2003127718 A RU 2003127718A RU 2003127718/15 A RU2003127718/15 A RU 2003127718/15A RU 2003127718 A RU2003127718 A RU 2003127718A RU 2003127718 A RU2003127718 A RU 2003127718A
- Authority
- RU
- Russia
- Prior art keywords
- flumazenil
- drug
- use according
- dependence
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Claims (10)
1. Применение флумазенила для производства лекарственного средства для лечения кокаиновой зависимости.
2. Применение по п.1, в котором лекарственное средство вводится последовательно через интервалы времени от 1 до 15 мин, обеспечивая введение от 0,1 до 0,3 мг флумазенила.
3. Применение по п.2, в котором лекарственное средство обеспечивает от 1,5 до 2,5 мг флумазенила в сутки.
4. Применение по п.2, в котором лекарственное средство обеспечивает введение 0,2 мг флумазенила.
5. Применение по п.2, в котором лекарственное средство вводится последовательно через интервалы времени 3 мин.
6. Применение по п.2, в котором лекарственное средство обеспечивает 2 мг флумазенила в сутки.
7. Применение по п.2, в котором лекарственное средство вводится перорально или парентерально.
8. Применение по п.2, в котором лекарственное средство вводится внутривенно.
9. Применение флумазенила для приготовления лекарственного средства для лечения кокаиновой зависимости, в котором лекарственное средство обеспечивает 0,2 мг флумазенила и вводится последовательно через интервалы времени 3 мин до обеспечения приблизительно 2 мг флумазенила в сутки.
10. Лекарственное средство для лечения кокаиновой зависимости, включающее дозу приблизительно 0,2 мг флумазенила.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200100342 | 2001-02-15 | ||
| ESP200100342 | 2001-02-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003127718A true RU2003127718A (ru) | 2005-01-27 |
| RU2322985C2 RU2322985C2 (ru) | 2008-04-27 |
Family
ID=8496743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003127718/15A RU2322985C2 (ru) | 2001-02-15 | 2002-02-08 | Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7186711B2 (ru) |
| EP (1) | EP1378267B1 (ru) |
| JP (2) | JP4272885B2 (ru) |
| KR (1) | KR100712571B1 (ru) |
| CN (1) | CN1327843C (ru) |
| AT (1) | ATE363923T1 (ru) |
| AU (1) | AU2002231811B2 (ru) |
| BR (1) | BR0207866A (ru) |
| CA (1) | CA2436511C (ru) |
| CY (1) | CY1106845T1 (ru) |
| DE (1) | DE60220512T2 (ru) |
| DK (1) | DK1378267T3 (ru) |
| ES (1) | ES2287255T3 (ru) |
| HK (1) | HK1061817A1 (ru) |
| IL (1) | IL157144A0 (ru) |
| MX (1) | MXPA03007281A (ru) |
| NZ (1) | NZ528164A (ru) |
| PT (1) | PT1378267E (ru) |
| RU (1) | RU2322985C2 (ru) |
| UA (1) | UA79586C2 (ru) |
| WO (1) | WO2002064213A1 (ru) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
| CA2436511C (en) | 2001-02-15 | 2009-08-04 | Juan Jose Legarda Ibanez | Use of flumazenil to produce a medicament for the treatment of cocaine dependency |
| WO2006110642A2 (en) * | 2005-04-07 | 2006-10-19 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
| US7855196B2 (en) | 2005-08-22 | 2010-12-21 | Pierre Mainville | Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist |
| ES2289935B1 (es) * | 2006-07-14 | 2008-12-16 | Juan Jose Legarda Ibañez | Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la patologia depresiva. |
| EP2186517A4 (en) * | 2007-08-08 | 2010-08-18 | Ibanez Juan Jose Legarda | USE AND METHODS OF USING A SEROTONIN3 (5-HT3) RECEPTOR ANTAGONIST AND CHLORIDE CHANNEL MODULATOR FOR THE TREATMENT OF DRUG OR DRUG ADDICTION OR DEPENDENCE OR CENTER NERVOUS DISORDERS |
| US9396280B2 (en) * | 2008-06-23 | 2016-07-19 | Microsoft Technology Licensing, Llc | Command driven web site browsing |
| AU2012221704B2 (en) | 2011-02-23 | 2013-12-05 | Coeruleus Ltd. | Flumazenil complexes, compositions comprising same and uses thereof |
| US9308616B2 (en) | 2013-01-21 | 2016-04-12 | Innovative Finishes LLC | Refurbished component, electronic device including the same, and method of refurbishing a component of an electronic device |
| WO2015054730A1 (en) * | 2013-10-14 | 2015-04-23 | Palmaya Pty Ltd | Compositions and methods of administering same |
| CN107115359A (zh) * | 2016-02-24 | 2017-09-01 | 郑恩哲 | 阻断海洛因或吗啡毒品中毒路径的点滴处方及其应用 |
| EP3661500A1 (en) | 2017-07-31 | 2020-06-10 | Novartis AG | Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028611A (en) * | 1989-06-29 | 1991-07-02 | The Regents Of The University Of Minnesota | Treatment for cocaine use |
| US5229120A (en) * | 1992-02-05 | 1993-07-20 | Devincent James F | Treatment for cocaine abuse |
| GB9420010D0 (en) | 1994-10-01 | 1994-11-16 | Marck Sharp & Dohme Limited | Nucleic acids |
| WO2000030648A1 (en) * | 1998-11-23 | 2000-06-02 | Sepracor Inc. | 2-hydroxymethylolanzapine compositions and methods |
| EP1125579A3 (en) * | 2000-01-18 | 2003-01-02 | Pfizer Products Inc. | Uses of agrp-melanocortin receptor binding modulating compounds |
| CA2436511C (en) | 2001-02-15 | 2009-08-04 | Juan Jose Legarda Ibanez | Use of flumazenil to produce a medicament for the treatment of cocaine dependency |
| US6740677B2 (en) | 2002-08-19 | 2004-05-25 | Hong Xue | Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids |
-
2002
- 2002-02-08 CA CA002436511A patent/CA2436511C/en not_active Expired - Fee Related
- 2002-02-08 PT PT02711879T patent/PT1378267E/pt unknown
- 2002-02-08 BR BR0207866-0A patent/BR0207866A/pt not_active Application Discontinuation
- 2002-02-08 KR KR1020037010718A patent/KR100712571B1/ko not_active IP Right Cessation
- 2002-02-08 ES ES02711879T patent/ES2287255T3/es not_active Expired - Lifetime
- 2002-02-08 JP JP2002564005A patent/JP4272885B2/ja not_active Expired - Lifetime
- 2002-02-08 NZ NZ528164A patent/NZ528164A/xx unknown
- 2002-02-08 WO PCT/ES2002/000061 patent/WO2002064213A1/es active IP Right Grant
- 2002-02-08 AT AT02711879T patent/ATE363923T1/de active
- 2002-02-08 CN CNB028049411A patent/CN1327843C/zh not_active Expired - Fee Related
- 2002-02-08 RU RU2003127718/15A patent/RU2322985C2/ru not_active IP Right Cessation
- 2002-02-08 MX MXPA03007281A patent/MXPA03007281A/es active IP Right Grant
- 2002-02-08 EP EP02711879A patent/EP1378267B1/en not_active Expired - Lifetime
- 2002-02-08 AU AU2002231811A patent/AU2002231811B2/en not_active Ceased
- 2002-02-08 DK DK02711879T patent/DK1378267T3/da active
- 2002-02-08 IL IL15714402A patent/IL157144A0/xx unknown
- 2002-02-08 DE DE60220512T patent/DE60220512T2/de not_active Expired - Lifetime
- 2002-08-02 UA UA2003098460A patent/UA79586C2/uk unknown
-
2003
- 2003-07-15 US US10/622,068 patent/US7186711B2/en not_active Expired - Lifetime
-
2004
- 2004-07-03 HK HK04104788A patent/HK1061817A1/xx not_active IP Right Cessation
-
2006
- 2006-12-22 US US11/615,460 patent/US20070142364A1/en not_active Abandoned
-
2007
- 2007-09-05 CY CY20071101148T patent/CY1106845T1/el unknown
-
2008
- 2008-04-30 JP JP2008117980A patent/JP2008201799A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ATE363923T1 (de) | 2007-06-15 |
| DE60220512T2 (de) | 2008-02-07 |
| JP2004521904A (ja) | 2004-07-22 |
| HK1061817A1 (en) | 2004-10-08 |
| CA2436511A1 (en) | 2002-08-22 |
| CA2436511C (en) | 2009-08-04 |
| UA79586C2 (en) | 2007-07-10 |
| JP4272885B2 (ja) | 2009-06-03 |
| JP2008201799A (ja) | 2008-09-04 |
| DE60220512D1 (de) | 2007-07-19 |
| BR0207866A (pt) | 2004-03-23 |
| WO2002064213A1 (es) | 2002-08-22 |
| MXPA03007281A (es) | 2005-01-25 |
| EP1378267A1 (en) | 2004-01-07 |
| KR100712571B1 (ko) | 2007-05-02 |
| EP1378267B1 (en) | 2007-06-06 |
| CN1327843C (zh) | 2007-07-25 |
| RU2322985C2 (ru) | 2008-04-27 |
| CN1491125A (zh) | 2004-04-21 |
| PT1378267E (pt) | 2007-09-11 |
| US20070142364A1 (en) | 2007-06-21 |
| ES2287255T3 (es) | 2007-12-16 |
| US20060122219A1 (en) | 2006-06-08 |
| DK1378267T3 (da) | 2007-10-08 |
| CY1106845T1 (el) | 2012-05-23 |
| NZ528164A (en) | 2006-03-31 |
| IL157144A0 (en) | 2004-02-08 |
| US7186711B2 (en) | 2007-03-06 |
| KR20040010592A (ko) | 2004-01-31 |
| AU2002231811B2 (en) | 2006-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9814378A (pt) | Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase | |
| ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| EA200501496A1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
| WO2005063297A3 (en) | Melatonin combination therapy for improving sleep quality | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| DE60209511D1 (de) | Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten | |
| MXPA05012810A (es) | Formas de dosis oral de memantina. | |
| CY1106845T1 (el) | Χρηση της φλουμαζενιλης για την παρασκευη ενος φαρμακου για την αγωγη της εξαρτησεως απο την κοκαϊνη | |
| DE60019436D1 (de) | Verwendung von nikotin oder derivaten und l-dopa zur behandlung von neurologischen krankheiten, insbesonder morbus parkinson | |
| RU2003125274A (ru) | Применение флумазенила в производстве лекарства для лечения алкогольной зависимости | |
| JP2004537500A5 (ru) | ||
| HUP0301828A2 (hu) | Apomorfin alkalmazása nemi mżködészavar meghatározott apomorfin-plazmakoncentrációval történż kezelésre szolgáló készítmények elżállítására | |
| IL194500A (en) | A peptide substance capable of increasing capillary resistance and pharmacological preparation containing the above | |
| PL1656131T3 (pl) | Zastosowanie betainy w leczeniu chromania przestankowego | |
| RU2007104774A (ru) | Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы | |
| BR0009380A (pt) | Tratamento de câncer melhorado comtemozolomida | |
| BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto | |
| RU2002124141A (ru) | Применение миртазапина для лечения расстройств сна | |
| RU2005131578A (ru) | Аплидин для лечения множественной миеломы | |
| RU2002129298A (ru) | Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| MXPA05007612A (es) | Uso de l-carnitina para el tratamiento de enfermedades cardiovasculares. | |
| CA2518205A1 (en) | Use of a fibrate and orlistat for the treatment of obesity | |
| DE60202299D1 (de) | Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20140209 |